- Home
- GORO vs ATNM Comparison
GORO vs ATNM Comparison
Compare GORO & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GORO
- ATNM
- Stock Information
- Founded
- GORO 1998
- ATNM 2000
- Country
- GORO United States
- ATNM United States
- Employees
- GORO N/A
- ATNM N/A
- Industry
- GORO Precious Metals
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- GORO Basic Materials
- ATNM Health Care
- Exchange
- GORO Nasdaq
- ATNM Nasdaq
- Market Cap
- GORO 53.3M
- ATNM 46.5M
- IPO Year
- GORO N/A
- ATNM N/A
- Fundamental
- Price
- GORO $0.49
- ATNM $1.38
- Analyst Decision
- GORO Strong Buy
- ATNM Strong Buy
- Analyst Count
- GORO 1
- ATNM 4
- Target Price
- GORO $1.25
- ATNM $8.75
- AVG Volume (30 Days)
- GORO 2.3M
- ATNM 1.4M
- Earning Date
- GORO 05-01-2025
- ATNM 04-25-2025
- Dividend Yield
- GORO N/A
- ATNM N/A
- EPS Growth
- GORO N/A
- ATNM N/A
- EPS
- GORO N/A
- ATNM N/A
- Revenue
- GORO $73,897,000.00
- ATNM N/A
- Revenue This Year
- GORO N/A
- ATNM N/A
- Revenue Next Year
- GORO $48.90
- ATNM N/A
- P/E Ratio
- GORO N/A
- ATNM N/A
- Revenue Growth
- GORO N/A
- ATNM N/A
- 52 Week Low
- GORO $0.12
- ATNM $1.03
- 52 Week High
- GORO $0.74
- ATNM $10.24
- Technical
- Relative Strength Index (RSI)
- GORO 49.20
- ATNM 48.59
- Support Level
- GORO $0.48
- ATNM $1.41
- Resistance Level
- GORO $0.66
- ATNM $2.41
- Average True Range (ATR)
- GORO 0.06
- ATNM 0.25
- MACD
- GORO -0.01
- ATNM -0.01
- Stochastic Oscillator
- GORO 19.29
- ATNM 17.60
About GORO Gold Resource Corporation
Gold Resource Corp is a gold and silver producer, developer, and explorer with operations in Oaxaca, Mexico, and Nevada, USA. It targets low capital expenditure projects with the potential for generating high returns on capital. The company's two pipeline projects are; Don David Gold at Oaxaca, Mexico, and Back Forty at Michigan, United States of America.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.